Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 May 16

PMID 37190065

Authors

Qitong Wu

Dipali Sharma

Affiliations

Soon will be listed here.

Abstract

Despite an increase in the incidence of breast cancer worldwide, overall prognosis has been consistently improving owing to the development of multiple targeted therapies and novel combination regimens including endocrine therapies, aromatase inhibitors, Her2-targeted therapies, and cdk4/6 inhibitors. Immunotherapy is also being actively examined for some breast cancer subtypes. This overall positive outlook is marred by the development of resistance or reduced efficacy of the drug combinations, but the underlying mechanisms are somewhat unclear. It is interesting to note that cancer cells quickly adapt and evade most therapies by activating autophagy, a catabolic process designed to recycle damaged cellular components and provide energy. In this review, we discuss the role of autophagy and autophagy-associated proteins in breast cancer growth, drug sensitivity, tumor dormancy, stemness, and recurrence. We further explore how autophagy intersects and reduces the efficacy of endocrine therapies, targeted therapies, radiotherapy, chemotherapies as well as immunotherapy via modulating various intermediate proteins, miRs, and lncRNAs. Lastly, the potential application of autophagy inhibitors and bioactive molecules to improve the anticancer effects of drugs by circumventing the cytoprotective autophagy is discussed.

Citing Articles

Raddeanin A promotes the apoptosis of gastric cancer in conjunction with autophagy inhibitor Hydroxychloroquine via MAPK signaling pathway.

Teng Y, Xing Y, Xue W, Hu Y, Li Z, Qian J J Tradit Complement Med. 2025; 15(2):161-169.

PMID: 40060151 PMC: 11883627. DOI: 10.1016/j.jtcme.2024.07.004.

Investigate of LOC101928988 Regulatory Effect on the DAPK2 Transcription in Breast Tumors.

Saberiyan M, Ghasemi N, Jafari N, Sadeghi M, Ghaderi A, Mousavi P Cancer Rep (Hoboken). 2025; 8(2):e70115.

PMID: 39971705 PMC: 11839281. DOI: 10.1002/cnr2.70115.

Resistance mechanisms and prospects of trastuzumab.

Wang L, Wang Y, Li Y, Zhou L, Du J, Wang J Front Oncol. 2024; 14:1389390.

PMID: 39655080 PMC: 11625751. DOI: 10.3389/fonc.2024.1389390.

Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis.

Shang J, Zhao F, Xie L, Wang Y, Li B, Jin C Open Med (Wars). 2024; 19(1):20241080.

PMID: 39655055 PMC: 11627063. DOI: 10.1515/med-2024-1080.

TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond.

Wu Q, Nandi D, Sharma D Cancer Metastasis Rev. 2024; 44(1):16.

PMID: 39644332 PMC: 11625080. DOI: 10.1007/s10555-024-10226-2.

References

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

Ni P, Zhang Y, Liu Y, Lin X, Su X, Lu H . HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis. Int J Clin Exp Pathol. 2016; 8(12):15940-6. PMC: 4730080. View

Gomez B, Riggins R, Shajahan A, Klimach U, Wang A, Crawford A . Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007; 21(14):4013-27. DOI: 10.1096/fj.06-7990com. View

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y . Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010; 16(2):214-8. PMC: 2826790. DOI: 10.1038/nm.2090. View

Flynn A, Calhoun B, Sharma A, Chang J, Almasan A, Schiemann W . Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019; 10(1):3668. PMC: 6694140. DOI: 10.1038/s41467-019-11640-9. View

Samanta D, Gilkes D, Chaturvedi P, Xiang L, Semenza G . Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014; 111(50):E5429-38. PMC: 4273385. DOI: 10.1073/pnas.1421438111. View

Massey A, Kiffin R, Cuervo A . Pathophysiology of chaperone-mediated autophagy. Int J Biochem Cell Biol. 2004; 36(12):2420-34. DOI: 10.1016/j.biocel.2004.04.010. View

Hatzis C, Pusztai L, Valero V, Booser D, Esserman L, Lluch A . A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011; 305(18):1873-81. PMC: 5638042. DOI: 10.1001/jama.2011.593. View

10.

Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P . Autophagy: for better or for worse. Cell Res. 2011; 22(1):43-61. PMC: 3351915. DOI: 10.1038/cr.2011.152. View

11.

He C, Klionsky D . Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43:67-93. PMC: 2831538. DOI: 10.1146/annurev-genet-102808-114910. View

12.

Kimura T, Takabatake Y, Takahashi A, Isaka Y . Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013; 73(1):3-7. DOI: 10.1158/0008-5472.CAN-12-2464. View

13.

Bushnell G, Deshmukh A, den Hollander P, Luo M, Soundararajan R, Jia D . Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer. 2021; 7(1):66. PMC: 8163741. DOI: 10.1038/s41523-021-00269-x. View

14.

Liao M, Qin R, Huang W, Zhu H, Peng F, Han B . Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022; 15(1):44. PMC: 9006445. DOI: 10.1186/s13045-022-01260-0. View

15.

Han M, Hu J, Lu P, Cao H, Yu C, Li X . Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020; 11(1):43. PMC: 6976584. DOI: 10.1038/s41419-020-2250-5. View

16.

Heng M, Detloff P, Paulson H, Albin R . Early alterations of autophagy in Huntington disease-like mice. Autophagy. 2010; 6(8):1206-8. PMC: 3039724. DOI: 10.4161/auto.6.8.13617. View

17.

Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y . Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006; 9(1):23-32. DOI: 10.1016/j.ccr.2005.12.012. View

18.

Liu H, Zang C, Emde A, Planas-Silva M, Rosche M, Kuhnl A . Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol. 2008; 591(1-3):43-51. DOI: 10.1016/j.ejphar.2008.06.026. View

19.

Ziaeemehr A, Shahidsales S, Ghosi Z, Avan A, Aldavood A, Anvari K . Association of the involvement of axillary lymph nodes in HER-2/neu overexpression in patients with breast cancer. Breast J. 2019; 25(3):537-538. DOI: 10.1111/tbj.13282. View

20.

Liu J, Cai M, Xin Y, Wu Q, Ma J, Yang P . Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010; 29:108. PMC: 2924280. DOI: 10.1186/1756-9966-29-108. View